Multiparametric High-resolution Ultrasound of the Breast
NCT ID: NCT03276845
Last Updated: 2017-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
124 participants
INTERVENTIONAL
2015-09-30
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However, in spite of defined morphological criteria for the differentiation of benign from malignant lesions, ultrasound of the breast also shows limitations regarding sensitivity and specificity. On the one hand, benign lesions may have one or more malignant characteristics and thus require a biopsy. On the other hand, malignant lesions can also show benign characteristics and thus make an accurate assessment difficult.
To overcome these limitations, newer sonographic methods have been developed. These include elastography, color and power Doppler imaging, contrast enhanced imaging and 3D sonography.
The application of elastography is based on the fact that cancer has a higher stiffness than healthy breast parenchyma.
In addition, cancers are characterized by neoangiogenesis and thus generally show an increased vascularization in color and power Doppler. The detection of neoangiogenesis can be improved by the application of contrast agents. The latter provides both morphological and functional information about tumors, through the study of the contrast agent kinetics.
Finally, 3D sonography allows for tumors to be examined in a third, coronal plane. This way, the interaction between the tumor and the surrounding healthy tissue can be better appreciated.
The objective of this study is the evaluation of suspicious (classified as BI-RADS 4 and 5) breast lesions by using high-resolution sonography, including elastography, color/power Doppler, contrast agent application and 3D sonography. Both morphological and functional information can thus be obtained. The primary hypothesis of this study is that this multiparametric approach will improve the detection and characterization of breast lesions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons
NCT00649337
Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies
NCT00721903
Multi-parametric Breast Ultrasound Imaging as a Potential Biomarker for Breast Cancer
NCT04480437
Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts
NCT02042456
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
NCT00721435
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Ultrasound of the breast
Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound of the breast
Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* Written informed consent
* Histopathological verification of the lesions either by core biopsy or by surgical excision
Exclusion Criteria
* Pregnant or lactating patients or patients with suspected pregnancy
* Known contraindication to the intravenous administration of US contrast agents
* Acute or chronic renal insufficiency
* Pre- or post-transplant patients
18 Years
99 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Panagiotis Kapetas
M.D.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Multiparametric breast US
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.